Peptido-mimetic inhibitor of apoptosis protein (IAP) antagonists (Smac mimetics (SMs)) can kill tumour cells by depleting endogenous IAPs and thereby inducing tumour necrosis factor (TNF) production. We found that interferon-γ (IFNγ) synergises with SMs to kill cancer cells independently of TNF − and other cell death receptor signalling pathways. Surprisingly, CRISPR/Cas9 HT29 cells doubly deficient for caspase-8 and the necroptotic pathway mediators RIPK3 or MLKL were still sensitive to IFNγ/SMinduced killing. Triple CRISPR/Cas9-knockout HT29 cells lacking caspase-10 in addition to caspase-8 and RIPK3 or MLKL were resistant to IFNγ/SM killing. Caspase-8 and RIPK1 deficiency was, however, sufficient to protect cells from IFNγ/SM-induced cell death, implying a role for RIPK1 in the activation of caspase-10. These data show that RIPK1 and caspase-10 mediate cell death in HT29 cells when caspase-8-mediated apoptosis and necroptosis are blocked and help to clarify how SMs operate as chemotherapeutic agents.
1
Mammalian IAPs can be antagonised by endogenous proteins such as Smac/DIABLO and HtrA2/Omi, 2, 3 and the finding that cell-permeable peptides containing the four N-terminal residues of Smac-sensitised tumour cells to apoptosis 4 hastened the development of synthetic Smac mimetics (SMs) that proved similarly efficacious. [5] [6] [7] [8] cIAPs play a central role in regulating tumour necrosis factor receptor 1 (TNFR1) signalling. Stimulation of TNFR1 by TNF promotes the formation of a membrane-bound intracellular signalling complex, Complex I, that can contain TRADD, 9, 10 RIPK1, 10, 11 TRAF2, 12 cIAP1/2 and LUBAC. 13 Several components of this complex become ubiquitylated by cIAPs and LUBAC. 2, 13, 14 This ubiquitylation provides a platform for the recruitment of IKK-and TAK1-containing complexes, ultimately resulting in the activation of NF-κB and MAP kinases and the transcription of prosurvival proteins and proinflammatory cytokines. 15 SM-induced cIAP degradation prevents ubiquitylation and formation of this ubiquitin platform. The failure to correctly form Complex I leads to the activation of caspase-8 in a secondary cytoplasmic complex (complex II) that contains TRADD, FADD and RIPK1 10 and apoptosis. The caspase-8 homodimer and the caspase-8/cFLIP L heterodimer that may also be present in complex II cleave RIPK1 and thereby prevent an alternative cell death pathway, called necroptosis. [16] [17] [18] [19] When caspase-8 is inhibited, or absent, necroptosis occurs following activation and autophosphorylation of RIPK1 and RIPK3. Active RIPK3 phosphorylates the pseudokinase MLKL, leading to its oligomerisation and MLKL-mediated membrane permeabilisation. 20 Similar to SMs, TWEAK, a TNF superfamily ligand, can synergise with TNF to kill tumour cells, [21] [22] [23] [24] and cells that are sensitive to TWEAK-induced death are also sensitive to SMs. 24 Earlier reports demonstrated that TWEAK not only synergises with cell death ligands such as TNF, TRAIL and Fas but also with interferon-γ (IFNγ) to kill cancer cells. 25, 26 Classical IFNγ receptor signalling, which involves the SOCS1-inhibitable JAK/STAT pathway, 27 differs significantly from typical cell death receptor pathways. It has however been implicated in causing apoptosis, 28, 29 and this has been attributed to, among other things, IFNγ-induced upregulation of proapoptotic proteins such as Puma, FasL, TRAIL 27, 30, 31 and caspase-8. 32 We hypothesised that, similar to TWEAK, SMs would synergise with IFNγ to induce cell death. We found that IFNγ/SM-induced death in primary mouse dermal fibroblasts (MDFs) occurred via RIPK3-and caspase-8-dependent apoptosis. However, human cell lines, and in particular human colorectal adenocarcinoma HT29 cells, behaved differently to MDFs. IFNγ/SM-induced killing of HT29 cells was not prevented by caspase inhibition. Furthermore, CASP8
HT29 cells from IFNγ/SM, indicating that this treatment induced a novel type of RIPK1-dependent cell death. We observed that caspase-10 was significantly upregulated following IFNγ treatment, and HT29 cells deficient for caspase-10, caspase-8 and either MLKL or RIPK3 were resistant to IFNγ/SM. This suggests that the human-specific caspase-10 may have an important role in IFNγ-induced death.
Results
IFNγ and SMs act synergistically to kill cancer cells. Consistent with earlier reports, we observed that IFNγ synergises with TWEAK to kill HT29, D645 and KATOIII cells 26 ( Figure 1a ). TWEAK and SMs cause similar cellular responses; 24, 33 ,34 therefore, we tested whether SM and IFNγ synergised to kill IFNγ/TWEAK-sensitive cells, which they did (Figure 1b) . Several other cell types were also sensitive to the combination of IFNγ/SM (Supplementary Figure S1A) . To test whether loss of a specific IAP was responsible for IFNγ/SMinduced cell death, we used primary MDFs and keratinocytes deficient for either XIAP, cIAP1 or cIAP2, and found that loss of individual IAPs did not sensitise cells to IFNγ death (Supplementary Figures S1B and C) . This suggests that pan-IAP inhibition is required for cell death induction.
IFNγ might synergise with SMs by enhancing SM-induced cIAP degradation. However, on the contrary, IFNγ treatment strongly increased the expression of cIAP2 in HT29s (Figure 1c ). IFNγ transcriptionally upregulates multiple genes via JAK-STAT and SMs activate NF-κB. 33, 34 We therefore tested whether transcription and protein synthesis are required for IFNγ/SM-induced killing. We inhibited protein synthesis with cycloheximide, and despite the fact that cycloheximide is toxic to cells (Figure 1d ), this treatment inhibited IFNγ/SM-induced death in HT29 and D645 cells (Figure 1d ). We inhibited NF-κB activation with an inducible IκBα super-repressor (IκB SR ) 33 and this reduced IFNγ/SMinduced death in HT29 and D645 cells (Figure 1e) . Similarly, overexpression of the JAK-STAT inhibitor SOCS1 protected HT29 and D645 cells from IFNγ/SM-induced cell death (Figure 1f) . These results demonstrated that transcription downstream of both NF-κB and JAK-STAT is required for IFNγ/ SM-induced death.
Death receptors are not essential for IFNγ/SM-induced killing. IAP antagonists cause cell death in some cells by promoting autocrine production of TNF and simultaneously sensitising them to the cytotoxic activity of TNF. 6, 7, 33, 34 IFNγ can also induce Fas and TRAIL 31, 35, 36 and both these ligands can synergise with SMs to kill cells. 5, 37 To investigate a potential role for autocrine FasL, TNF or TRAIL in IFNγ/SMinduced killing, we preincubated cells with blocking antibodies. These antibodies blocked cell death induced by high doses of recombinant FasL-and TRAIL-as well as TNF/SMinduced cell death (Supplementary Figure S2) . However, IFNγ/SM-induced cell death could not be blocked by single or combined treatment with neutralising FasL, TNF or TRAIL antibodies (Figure 2a) .
We also analysed primary MDFs and keratinocytes, isolated from mutant and knockout mouse strains that were deficient for cell death ligands and receptors. Fasl gld/gld Tnf -− / − and Ifnar − / − MDFs, and Tnf Figure S3D) .
To determine the type of cell death induced by IFNγ/SM, we generated primary MDFs lacking key mediators in the , suggesting a necroptosis-independent role for RIPK3 that is not wholly unprecedented. 41, 42 Both Ripk3
Casp8 − / − MDFs were completely resistant to IFNγ/ SM-induced cell death, suggesting that IFNγ/SM treatment causes a caspase-8-dependent apoptosis ( Figure 3a ). Inhibition of necroptosis using the MLKL inhibitor, compound 1, 43 and the RIPK1 inhibitor, Nec-1 (necrostatin-1), 44 had no impact on the sensitivity to IFNγ/SM killing (Figure 3b ), but provided some protection when combined with the caspase inhibitor, QVD ( Figure 3c ). QVD alone did not stop IFNγ/SM killing because by preventing apoptosis it triggered necroptosis ( Figure 3c ). We consistently detected TNF-dependent reduction of RIPK1 levels in MDFs upon IFNγ/SM plus QVD treatment, indicating that the absence of IAPs and inhibition of caspases destabilises RIPK1 (Figure 3d ). Overall, these data revealed that in MDFs, IFNγ/SM treatment primarily activates RIPK3, which is followed by caspase-8 activation. This is further supported by the reduction of caspase-8 processing in Ripk3 − / − MDFs compared with wild-type MDFs detected by western blotting (Figure 3d ). If, however, apoptosis is inhibited, then necroptosis occurs. Hence, both caspase-8-mediated apoptosis and necroptosis must be blocked to protect MDFs from IFNγ/SMinduced cell death.
IFNγ/SM triggers necroptosis in HT29 cells when caspases are inhibited. In contrast to MDFs, QVD protected D645 cells from IFNγ/SM-induced death (Figure 4a ). Similar to MDFs, however, HT29 and KATOIII cells still underwent cell death in the presence of caspase inhibitors (Figure 4a ). To assess whether this caspase-independent cell death was necroptosis, we inhibited RIPK1 using Nec-1. 44 Nec-1 alone did not prevent cell death, while the combination of QVD and Nec-1 provided protection in KATOIII cells, but had little impact on death in HT29 cells (Figure 4a ). These results suggested that HT29 cells exhibited a different type of cell
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− / − Casp8 − / − and Tnfr1 − / − MDFs were treated with IFNγ/SM, QVD and Nec-1 for 24 h similar to that in (b) and (c). Total cell lysates were analysed by immunoblotting (n = 2). Arrows indicate full-length and processing products of caspases death in response to IFNγ/SM, such as autophagy. However, when we knocked down the autophagy mediator ATG5 (autophagy protein 5) or treated these cells with autophagy inhibitors (Supplementary Figures S4A and B) , we failed to detect any effect on IFNγ/SM killing.
While inhibitors can provide insights, genetic experiments generally have fewer caveats. We therefore generated singlecell HT29 clones deficient for apoptotic (CASP8
) cell death pathways using CRISPR/Cas9 45, 46 and validated them using next-generation sequencing (Supplementary Figure S5) . Similar to their wild-type counterparts, CASP8
− / − HT29 cells were sensitive to IFNγ/SM treatment (Figure 4b) . In other systems, this would be explained by the fact that loss of caspase-8 leads to the induction of necroptosis; however, Nec-1 had no impact on IFNγ/SM-induced death of CASP8 
CASP8
− / − HT29 cells following IFNγ/SM treatment, which was reduced by QVD (Figure 5b ). Taken together, these data suggest that a Nec-1-independent RIPK1 activity is required for a caspase-dependent IFNγ/SM-induced cell death.
Caspase-10 mediates cell death in the absence of caspase-8 and necroptosis. Despite some conflicting data, it appears that caspase-10 can act as an initiator caspase in extrinsic apoptosis pathways. 10, 47, 48 To evaluate a role for caspase-10 in IFNγ/SM-induced cell death, we immunoblotted for caspase-10 and observed markedly increased levels when HT29 cells were treated with IFNγ for 24 h (Figure 6a ). HT29 cells treated with IFNγ/SM also upregulated caspase-10, and various cleaved forms were detected (Figure 6a) . Addition of the pancaspase inhibitor IDN-6556, a more potent caspase inhibitor than QVD, 49 prevented the formation of the smallest processed product of caspase-10 (p25), which served as the clearest signature of caspase-10 activation (Figure 6a (Figure 6a) , and both caspase-10 and caspase-3 processing were blocked by IDN-6556. Thus, in the absence of caspase-8 and necroptosis effectors, caspase-10 is strongly activated and caspase-3 is an excellent substrate for it.
Caspase-10 upregulation and activation upon IFNγ or IFNγ/SM stimulation was not restricted to HT29s because we also observed it in melanoma, glioblastoma, monocytic and other colon cancer cell lines (Supplementary Figures S8A-G) . To determine the contribution of caspase-10 to IFNγ/SM-induced cell death, we generated HT29 single-cell clones lacking caspase-10 (Supplementary Figure S5) . CASP10
− / − cells were as sensitive as the parental HT29 cells when treated with IFNγ/SM (Figure 6b) . Similarly, double deficiency of RIPK3 and caspase-10 or MLKL and caspase-10 in HT29 cells had no effect on the extent of cell death induced by IFNγ/SM, but these cells were now well protected from cell death when IDN-6556 was added (Figure 6b ). Most importantly, RIPK3
HT29 cells were largely resistant to IFNγ/SM-induced cell death (Figure 6b) . Consistent with this, we failed to detect an IFNγ/SMinduced increase in cleaved caspase-3 in triple-knockout cells (Figure 6c ). Collectively, these data demonstrate that IFNγ/SM primarily triggers extrinsic apoptosis through activation of caspase-8 and caspase-10. If caspase-8-mediated apoptosis is prevented, then necroptosis occurs. HT29 cells unable to undergo caspase-8 mediated apoptosis and classic necroptosis can, however, still die via caspase-10.
Caspase-10 requires RIPK1 to induce cell death and cleaved caspase-10 is detected in a caspase-8-containing complex in HT29 cells. Caspase-10 has been shown to be recruited to the Ripoptosome complex upon TNF stimulation. 10, 50 To examine whether a similar complex forms upon IFNγ/SM treatment, we immunoprecipitated caspase-8 ( Figure 7a and Supplementary Figure S7B) . Because caspase Figure 7b ). The smallest caspase-10 product was not detected when RIPK1 and caspase-8 were absent (Figure 7b ). Reduced activation of caspase-10 coincided with reduced caspase-3 processing when RIPK1 − / − CASP8 − / − cells were stimulated with IFNγ/SM (Figure 7b ). This suggests that independent of its function in necroptosis, RIPK1 is required for full caspase-10 activation in the context of IFNγ/SM stimulation.
Discussion
TNF binding to its receptor TNFR1 induces recruitment of a number of components including cIAPs and RIPK1. 15 Subsequent ubiquitylation of RIPK1 by cIAPs and LUBAC provides a binding platform for kinases such as TAK1, leading to NF-κB and MAPK signalling and upregulation of prosurvival proteins. Degradation of cIAPs induced by SMs stops efficient formation of the TNFR1 signalling complex and prevents 
− / − HT29 cells were treated as indicated for 24 h, lysed in SDS lysis buffer and immunoblotted. Arrows indicate full-length and processing products of caspases upregulation of prosurvival proteins. RIPK1, TRADD, FADD, caspase-8 and, in human cells, the less studied caspase-10 form a cytoplasmic complex (complex II), which can lead to caspase activation and apoptosis. 10, 50 Active caspase-8 not only induces apoptosis but also inhibits necroptosis, predominantly as a heterodimer with cFLIP, by cleaving RIPK1. Therefore, blocking caspase-8 not only prevents apoptosis but also unleashes the brake on RIPK1, allowing necroptosis to occur. 19, 52, 53 cIAPs also inhibit activation of noncanonical NF-κB and SMs can thereby cause production of autocrine TNF. 6, 7, 33, 34 Thus, in some cells, SMs can induce cell death by simultaneously up regulating TNF production and sensitising those same cells to TNF-induced cell death.
The TNF superfamily ligand TWEAK, which, upon binding to its receptor Fn14, promotes depletion of cIAPs in a manner analogous to SMs, can also induce TNF in a subset of cells and sensitise them to TNF killing. 24 IFNγ also has an apoptotic activity in some cell types, 54 and the pivotal role of IFNγ in inhibiting tumour cell growth has recently been highlighted by new studies showing that tumours resistant to checkpoint therapy acquire mutations in the IFNγ signalling pathway. 55, 56 We were intrigued by two old reports showing that IFNγ and TWEAK synergise to kill tumour cell lines. 25, 26 We confirmed these original observations and found that SMs can also synergise with IFNγ to kill cells. IFNγ can transcriptionally upregulate target genes and this was essential for IFNγ/SM killing because this death could be blocked by SOCS1 overexpression. We suspected that IFNγ/SM-induced TNF caused cell death; however, blocking TNF had no effect on IFNγ/SM killing. IFNγ can also induce FasL and TRAIL 54 and these can synergise with SMs to kill cells. 4, 37 However, blocking TNF, Fas and TRAIL did not prevent IFNγ/SM-induced cell death.
Although PKR has been claimed to have a role in IFNγ-induced cell death, 29 Figures S6A and B) . This makes it difficult to be sure which is the 'correct' phenotype. We believe that the sensitive phenotype is the relevant phenotype because first IFNγ/SMinduced cell death of HT29 cells could not be blocked by Q-VD-OPh (QVD) and second even combined loss of RIPK3 or MLKL and caspase-8 did not prevent IFNγ/SM-induced death. Because we only ever observed a sensitive phenotype in CASP8
RIPK3
− / − and CASP8 − / − MLKL − / − HT29 cells, we hypothesise that the resistant CASP8 − / − clones acquired additional changes that allowed them to overcome an unstable state caused by caspase-8 deficiency.
IFNγ/SM treatment of CASP8
MLKL − / − cells induced substantial amounts of cleaved caspase-3. The human-specific caspase-10 can activate caspase-3, 58, 59 suggesting that it might be involved in IFNγ/SM killing. Supporting this hypothesis, we found that caspase-10 was strongly induced by IFNγ in HT29 and several other cell lines. Furthermore, IFNγ/SM treatment induced processing of caspase-10. However, loss of caspase-10 alone did not reduce IFNγ/SM-induced death, and neither did it promote necroptosis. Nevertheless, CASP8 This study highlights how complex cell death pathways can be and their resilience to disruption, perhaps reflecting the defensive nature of cell death. Intriguingly, immune checkpoint inhibitors appear to require tumour cell intrinsic IFNγ signalling to cure melanomas in patients 55, 56 and it was proposed that this was, in part, due to the apoptotic activity of IFNγ. Because IFNγ upregulates caspase-10 in multiple cell lines including human melanoma cell lines, and that this contributes to SM-induced killing our results open up the enticing possibility that SMs could be combined with immune checkpoint inhibitors to increase T-cell killing by synergising with T-cell-secreted IFNγ.
Materials and Methods
Cell culture, transfection, lentiviruses and lentiviral production. MDFs and keratinocytes were generated as per Gerlach et al.
14 and Etemadi et al. 60 and similar to 239Ts cultured in Dulbecco's modified Eagle's medium with the addition of 8% FBS, 1 mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin (purchased from Gibco, Melbourne, VIC, Australia) at 37°C with 10% CO 2 in a humidified incubator. All other cell lines were cultured in HTRPMI, respectively, with additives and conditions like that described above.
The inducible lentiviral system has been described, 33 but briefly the inducible transcriptional activator Gal4 ER T2 VP16 (GEV16) was cloned into the lentiviral vector pFU PGK Hygro and infected with pF 5x UAS SV40 Puro vectors encoding for human IκB SR61 and human SOCS1 in HT29 and D645 cells. The cDNA encoding for human PKR was purchased by Addgene (Cambridge, MA, USA) and was cloned into the pFTRE 3G vector, which was generated by Toru Okamoto, and allows doxycyclineinducible expression.
For the generation of the CRISPR/Cas9 cell lines, we used two vectors generated by Marco Herold: the vector pFU Cas9 Cherry, which allows constitutive expression of the Cas9 protein, and the pF GH1t UTG vector, which allows doxycycline-inducible expression of different guide RNA sequences complementary to their target sequence. 46 Infected cells were selected with 5 μg/ml of puromycin (for IκBα SR , SOCS1, PKR selection) and/or 10-50 μg/ml of hygromycin (for GEV16 selection) or single cells were sorted for GFP and mCherry (selection of CRISPR/Cas9 cell lines) into 96-well plates. Lentiviral constructs were induced with 10 nM of 4-hydroxy tamoxifen or 20 ng/ml (for pFTRE 3G human PKR vector) and 1 μg/ml (for pF GH1t UTG vector) doxycycline.
To knock down ATG5 in HT29 cells, cells were infected with pLKO.1 encoding for the shRNA against ATG5, which is constitutively expressed.
